Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary
Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary
复制标题
DOI：
10.1016/j.ajog.2008.04.004
复制
发表时间：
2008-11-01
影响因子：
9.8
通讯作者：
Staff, Anne Cathrine
中科院分区：
文献类型：
--
作者：
Odegaard, Elin;Davidson, Ben;Staff, Anne Cathrine
目的：本研究的目的是分析卵巢癌患者循环内皮糖蛋白的浓度，并评估钙卫蛋白和内皮糖蛋白在晚期疾病渗出液中的预后作用。良性卵巢肿瘤（n = 71）、交界性卵巢肿瘤（n = 71）患者术前血浆内皮素浓度用酶联免疫吸附试验分析了164例晚期卵巢癌患者（BOT，n = 39）和卵巢癌患者（n = 89）的渗出液中内皮糖蛋白和钙卫蛋白的浓度。BOT组内皮素血浆浓度中位数高于对照组和浸润性癌组（4.9 vs 4.5和4.3 ng/mL，P = .04和P = .02），而对照组和侵袭组之间的差异无统计学意义（4.5 vs 4.3 ng/mL，P = 0.08）。内皮糖蛋白和钙卫蛋白渗出液浓度与生存率无关。结论：循环内皮糖蛋白在晚期卵巢癌中不升高。这与乳腺癌和胃癌的情况相反。
OBJECTIVE: The objective of the study was to analyze circulating endoglin concentration in ovarian carcinoma and evaluate a prognostic role for calprotectin and endoglin in effusions in advanced-stage disease.STUDY DESIGN: Preoperative plasma concentration of endoglin from women with benign ovarian tumors (n = 71), borderline ovarian tumors (BOT, n = 39), and ovarian carcinomas (n = 89) was analyzed with an enzyme-linked immunosorbent assay, as were endoglin and calprotectin concentrations in effusions from 164 women with advanced-stage ovarian carcinoma.RESULTS: Median endoglin plasma concentration was higher in the BOT group as compared with both control and invasive carcinoma groups (4.9 vs 4.5 and 4.3 ng/mL, P = .04 and P = .02), whereas the difference between the control and invasive group was not statistically significant (4.5 vs 4.3 ng/mL, P = .08). Endoglin and calprotectin effusion concentrations did not correlate with survival.CONCLUSION: Circulating endoglin is not elevated in advanced ovarian carcinoma. This is in contrast to the situation in breast and gastric cancer.